Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma
NCT01446562
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Follicular Lymphoma
Interventions
BIOLOGICAL:
Y90 Ibritumomab Tiuxetan RIT
Sponsor
Sunnybrook Health Sciences Centre